News Releases

September 12, 2023   A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC

September 7, 2023   NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen

September 5, 2023   Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease

August 31, 2023   NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference

August 3, 2023   NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results

June 21, 2023   NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting

May 9, 2023   NextCure to Present at the JMP Securities Life Sciences Conference

May 4, 2023   NextCure Provides Business Update and Reports First Quarter 2023 Financial Results

April 11, 2023   NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference

March 2, 2023   NextCure Provides Business Update and Reports Full Year 2022 Financial Results